As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
|Videos|January 31, 2019
PRRT And The Neuroendocrine Tumor Treatment Algorithm
Author(s)Shishir K. Maithel, MD, FACS
Cancer Network spoke with Dr. Shishir Maithel about grading and diagnosing neuroendocrine tumors and how PRRT best fits into the treatment algorithm of these tumors.
Advertisement
Cancer Network spoke with Dr. Shishir Maithel about grading and diagnosing neuroendocrine tumors and how PRRT best fits into the treatment algorithm of these tumors.
Advertisement
Related to this article
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.